Blog | HemaCare

HemaCare PBMCs used for 3D Anti-Tumor Discovery Platform

Sep 28, 2021 10:30:00 AM / by Nancy Andon, MSc posted in Cryopreservation, PBMCs, T Cells, Immunotherapy (Immunology)


An independent publication cites the use of HemaCare-sourced PBMC as starting material for an assay designed to screen for factors that enhance anti-tumor cytotoxic T cell activity. [1]

The paper, published in the renowned scientific journal Nature, reports the study results of a scientific team working at Novartis in San Diego. Their goal is to develop a discovery platform that more closely mimics the in-vivo tumor microenvironment.

Read More

The Beginners Guide to COVID-19 mRNA Vaccines

Aug 17, 2021 10:30:00 AM / by Nancy Andon, MSc posted in Cryopreservation, PBMCs, Serum, Plasma


Part 1: What is an mRNA Vaccine?

Vaccination is one of the most successful public health initiatives in history. Vaccine-preventable diseases are at or near an all-time low. So why are some people so hesitant to receive the COVID-19 vaccine?

It turns out that vaccine hesitancy is as old as vaccination itself. The unknown can be scary, and while modern humans may live in the “Age of Information”, most of us realize that not all information is reliable. Fortunately, help is on the way! In this 2-part blog series, the experts at HemaCare break down precisely what a mRNA vaccine is and how it works to protect those who get it.

Read More

COVID-19 Vaccine Series Launch Heralds New Era of Research

Aug 10, 2021 10:15:00 AM / by Nancy Andon, MSc posted in Cryopreservation, PBMCs, Serum, Plasma


The COVID-19 pandemic upended daily lives around the world. Now that we have working vaccines, a new phase has begun in the battle against the deadly virus. Scientists are striving to gather in-depth information about vaccine immune response.

Data collected at the University of Oxford [1] shows that approximately 30.0% of the world population has received at least one COVID-19 vaccine, while just over 15.5% are fully vaccinated. Less developed countries lag far behind more developed nations in their vaccination rates. Only 1.1% of people in low-income countries have received at least one vaccine dose, while the most developed nations are now reaching vaccination rates of 60-70% of their population. [1] And even while countries race to vaccinate as many people against COVID-19 as possible, new strains of the virus are emerging, while vaccine hesitancy slows the global effort to eradicate the disease.

Read More

Cryopreserved Immune Cells Tip the Scales Toward Success

Apr 27, 2021 10:33:51 AM / by Nancy Andon, MSc posted in Cell Therapy, Cryopreservation


The cell therapy industry is enjoying a period of unprecedented growth. The number of cell-based treatments transitioning from development to commercial manufacturing is forecast to continue growing dramatically over the next decade. This predicted growth rate can only be maintained by a parallel increase in the availability of therapeutic starting materials.

Read More

HemaCare Leukopaks Aid T Cell Cryopreservation Study

Apr 30, 2019 10:00:00 AM / by Nancy Andon, MSc posted in Leukopak, CAR-T, Cell Therapy, Cryopreservation, T Cells


An independent publication in Nature: Scientific Reports cites using fresh leukopaks sourced from HemaCare in their T cell cryopreservation study. The authors, who work at the Cell and Gene Therapy Catapult in London, are studying the impact of cooling and thawing rates on cryopreserved human peripheral blood-derived T cells. In order for the emerging cell and gene therapy industry to effectively ship and store cell-based therapies to global markets, it will be necessary to cryopreserve cell therapy starting materials, as well as the final therapeutic products. To retain peak cellular function, and therefore therapeutic efficacy upon patient administration, it is necessary to understand how to optimize the cryopreservation process.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts